Possible effect of dihydropyridines on topoisomerase-mediated multidrug resistance, a new approach for designing the new reversal agents for atypical MDR

Multidrug resistance can result from several factors and processes. Some types of multidrug resistance (MDR) were recognized whose patterns differ from pattern of P-glycoprotein (P-gp) associated MDR in several important ways. Although, there is limited evidence for effect of DHP on atypical MDR; based on some observations like noncompetitive inhibition of topoisomerase I by a DHP derivative (Dexniguldipine), it has been hypothesized that some DHP derivatives which have essential structural feature have possible effect on altering the topoisomerase II levels or activity which results in reversing topoisomerase-mediated MDR. If this hypothesis is verified, some new dihydropyridine can be synthesized with possible dual effect on both typical and atypical MDR.